| human | Q5 |
| P496 | ORCID iD | 0000-0002-7790-1611 |
| P1053 | ResearcherID | B-9636-2008 |
| P735 | given name | Henry | Q1158477 |
| Henry | Q1158477 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q59357922 | A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B |
| Q84583821 | A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B |
| Q81254816 | A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients |
| Q37541594 | A review of the natural history of chronic hepatitis B in the era of transient elastography. |
| Q46611928 | Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. |
| Q33988586 | Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development |
| Q91305142 | Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy |
| Q34518417 | Changing scene in hepatitis B serology interpretation |
| Q37825657 | Chronic hepatitis B in Asia-new insights from the past decade |
| Q38113179 | Chronic hepatitis B: a treatment update |
| Q91041961 | Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment |
| Q46176187 | Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. |
| Q39896037 | Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. |
| Q86674169 | Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial |
| Q40224995 | Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong |
| Q82648058 | Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease |
| Q35791636 | Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy |
| Q84484058 | Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years |
| Q57051373 | Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients-same score, different outcomes. Author's Reply |
| Q95643115 | Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors' reply |
| Q83042380 | Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial |
| Q93338958 | Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus |
| Q82209303 | Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B |
| Q38135646 | Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease |
| Q37214128 | Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma |
| Q89596967 | Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B |
| Q30747665 | Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging |
| Q40116518 | Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients |
| Q46531274 | Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people |
| Q37896235 | Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report |
| Q43291466 | Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. |
| Q34773725 | Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients |
| Q36180475 | Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment |
| Q36467980 | Hepatocellular carcinoma and hepatitis B virus |
| Q46009901 | High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. |
| Q51054700 | High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. |
| Q39997004 | High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. |
| Q35532673 | Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong |
| Q39658315 | Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients |
| Q59353326 | Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B |
| Q91534593 | Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma |
| Q45811793 | Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. |
| Q40284621 | Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. |
| Q97530994 | Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 |
| Q91365317 | Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease |
| Q39332284 | Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. |
| Q46478755 | Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. |
| Q51492450 | Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. |
| Q40528074 | Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. |
| Q90058766 | Modelling NAFLD disease burden in four Asian regions-2019-2030 |
| Q34702127 | Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study |
| Q36027130 | Molecular virology in chronic hepatitis B: genotypes |
| Q74112680 | Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection |
| Q44895107 | Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. |
| Q38731060 | Pathogenesis and novel treatment options for non-alcoholic steatohepatitis |
| Q41788195 | Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region. |
| Q38000490 | Prevention of hepatocellular carcinoma: a concise review of contemporary issues. |
| Q90347922 | Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy |
| Q46367959 | Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. |
| Q37798474 | Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital |
| Q39169232 | Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong |
| Q35580986 | Reimbursement policies in the Asia-Pacific for chronic hepatitis B. |
| Q89063458 | Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness |
| Q52665321 | Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. |
| Q47550018 | Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. |
| Q51039388 | Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. |
| Q38321507 | Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. |
| Q96581137 | Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients |
| Q45398888 | Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. |
| Q33385813 | Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease |
| Q102321255 | Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss |
| Q40158777 | Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. |
| Q41931638 | Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. |
| Q53028105 | Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. |
| Q59353203 | Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study |
| Q90119852 | Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis |
| Q39410610 | The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment |
| Q47380863 | The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C. |
| Q33981411 | The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity |
| Q41930099 | The impact of diabetes mellitus and hepatitis B virus co-infection on patients with chronic hepatitis C - a territory-wide cohort study. |
| Q36419017 | The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. |
| Q38940951 | The role of quantitative hepatitis B surface antigen revisited. |
| Q37805637 | Transient elastography |
| Q58235659 | Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study |
| Q91953103 | Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B |
| Q34173092 | Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. |
| Q51444679 | Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. |
| Q98950391 | Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis |
| Q36958940 | Virus and Host Testing to Manage Chronic Hepatitis B. |
Search more.